Nikhil Agrawal

Company: AstraZeneca

Job title: Global Development Medical Director

Seminars:

Panel Discussion | From Slowing Progression to Halting Entirely: Debating the “What’s Next” for Diabetic, Hypertensive & Rare Kidney Diseases 3:30 pm

From SGLT2s and ERAs, to GLP1s and anti-APRIL: where is the field heading next? Evaluating the most exciting opportunities for new treatment options Shifting the focus towards more pivotal therapies specific to underlying kidney pathophysiology, with an end goal of stopping, rather than slowing, CKD progressionRead more

day: Conference Day 2

APOL1 Related Kidney Disease: Navigating the Heterogeneity of CKD Populations Through Genetic Testing to Develop Targeted Therapies 1:30 pm

The unmet need: genetics and epidemiology of Apol1 in CKD Identifying the target population: pathophysiology of Apol1 kidney disease Overview of therapies currently in developmentRead more

day: Day 1 Track 2 PM